Methods for treating pulmonary fibrosis
OwnerBruce D. Uhalinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to uses of non-thiol ACE inhibitors, angiotensin II antagonists, angiotensin II receptor antagonists, endonuclease inhibitors, and caspase-inhibitors to treat pulmonary fibrosis and/or inhibit pulmonary epithelial cell apoptosis, including pulmonary fibrosis associated with amiodarone product toxicity.
Claims35
A method of treating a pulmonary fibrotic disease comprising administering to a subject at risk of or suffering from a pulmonary fibrotic disease an amount of an antagonist of the renin-angiotensin-aldosterone system effective to inhibit pulmonary epithelial cell apoptosis, wherein said antagonist is not a thiol ACE inhibitor.
A method of treating a pulmonary fibrotic disease comprising administering to a subject at risk of or suffering from a pulmonary fibrotic disease a pharmaceutically effective amount of an antagonist of the renin-angiotensin-aldosterone system, wherein said antagonist is not a thiol ACE inhibitor.
A method of treating a pulmonary fibrotic disease comprising administering to a subject at risk of or suffering from a pulmonary fibrotic disease a pharmaceutically effective amount of a caspase enzyme inhibitor or endonuclease inhibitor.
A method of identifying a novel therapeutic compound for treating pulmonary fibrotic disease comprising the steps of:
- (a) measuring apoptosis of mammalian pulmonary epithelial cells in the presence and absence of a test compound;
- (b) selecting a test compound that inhibits apoptosis of said cells;
- and
- (c) determining an effect of said test compound selected in step (b) in an animal model of pulmonary fibrosis.
A method of identifying a novel therapeutic compound for treating pulmonary fibrotic disease comprising the steps of:
- (a) measuring the interaction of a test compound with a member of the renin-angiotensin-aldosterone system, wherein said member of the renin-angiotensin-aldosterone system is other than angiotensin converting enzyme (ACE);
- (b) selecting a test compound that interacts with said member of the renin-angiotensin-aldosterone system;
- and
- (c) determining effect of the test compound selected in step (b) in an animal model of pulmonary fibrosis.
A method of identifying a novel therapeutic compound for treating pulmonary fibrotic disease comprising the steps of:
- (a) measuring the activity of angiotensin converting enzyme (ACE) in the presence and absence of a test compound;
- (b) selecting a test compound that inhibits ACE;
- and
- (c) measuring apoptosis of mammalian pulmonary epithelial cells in the presence and absence of said test compound selected in step (b).
A method of treating a human subject in need thereof comprising the steps of administering a dose of an amiodarone product higher than an amiodarone-equivalent dose of 1600 mg/day and administering an antagonist of the renin-angiotensin-aldosterone system or an apoptosis inhibitor.
A method of treating a human subject in need thereof comprising the steps of administering an amiodarone product at doses maintaining an amiodarone-equivalent mean serum concentration of higher than about 1.8 μg/mL and administering an antagonist of the renin-angiotensin-aldosterone system or an apoptosis inhibitor.
A method of reducing adverse effects resulting from administration of an amiodarone product to a subject comprising administering to said subject an antagonist of the renin-angiotensin-aldosterone system or an apoptosis inhibitor in an amount effective to reduce adverse effects of amiodarone product administration.
Dependencies are inferred from the claim text.